Publications by authors named "Jay L Tuttle"
Article Synopsis
- Mirikizumab is a monoclonal antibody that targets IL-23 and showed effectiveness and good tolerance in a phase 2 clinical trial for patients with moderate-to-severe ulcerative colitis.
- In the trial, patients received either mirikizumab or a placebo, and their colonic tissue was analyzed for gene expression changes over a 12-week period.
- Results showed that the 200 mg mirikizumab group had significant improvements in clinical outcomes, with changes in gene transcripts linked to disease activity and resistance to current therapies, providing insight into how IL-23 inhibition aids healing in ulcerative colitis.
As the coronavirus disease 2019 (COVID-19) pandemic evolves and vaccine rollout progresses, the availability and demand for monoclonal antibodies for the prevention and treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are also accelerating. This longitudinal serological study evaluated the magnitude and potency of the endogenous antibody response to COVID-19 vaccination in participants who first received a COVID-19 monoclonal antibody in a prevention study. Over the course of 6 months, serum samples were collected from a population of nursing home residents and staff enrolled in a clinical trial who were randomized to either bamlanivimab treatment or placebo.
View Article and Find Full Text PDFArticle Synopsis
- Mirikizumab, a monoclonal antibody targeting interleukin 23p19, shows promise in treating moderate-to-severe Crohn's disease (CD), with demonstrated effectiveness in earlier studies on psoriasis and ulcerative colitis.
- In a study with 191 patients, those receiving mirikizumab had a significantly better endoscopic response at Week 12 compared to placebo, particularly at the 600 mg and 1000 mg doses.
- Safety profiles for mirikizumab were comparable to placebo, although there were higher rates of serious adverse events in certain nonrandomized groups, indicating the necessity for careful monitoring.
The efficient community spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in the current pandemic of coronavirus disease-2019 (COVID-19), which in severe and critical cases results in progressive pulmonary infection, complicated by respiratory failure, with a high prevalence of acute respiratory distress syndrome. Of all age groups, older adults have the greatest risk of severe COVID-19 and the associated complications. Globally, there are many reports of the rapid spread of COVID-19 among residents of skilled nursing facilities, with high associated rates of morbidity and mortality.
View Article and Find Full Text PDFImportance: Preventive interventions are needed to protect residents and staff of skilled nursing and assisted living facilities from COVID-19 during outbreaks in their facilities. Bamlanivimab, a neutralizing monoclonal antibody against SARS-CoV-2, may confer rapid protection from SARS-CoV-2 infection and COVID-19.
Objective: To determine the effect of bamlanivimab on the incidence of COVID-19 among residents and staff of skilled nursing and assisted living facilities.
Article Synopsis
- The study focused on mirikizumab, an antibody targeting interleukin 23, and its effectiveness in treating moderate to severe ulcerative colitis after an initial 12-week trial period.
- In the extended open-label study, patients who initially did not respond to mirikizumab were given higher doses (600 mg or 1000 mg) for another 12 weeks.
- Results showed that around 50% of patients receiving 600 mg and 43.8% receiving 1000 mg achieved a clinical response, with some going on to a maintenance period with lower doses.
Article Synopsis
- Interleukin 23 is linked to ulcerative colitis (UC), and a phase 2 study was conducted to assess the monoclonal antibody mirikizumab's effectiveness on UC patients across 14 countries from 2016 to 2017.
- Patients with moderate to severe UC were randomly assigned to receive either mirikizumab at different doses or a placebo, with the primary goal being to achieve clinical remission by week 12.
- The study found that while some patients on mirikizumab showed clinical responses, the primary endpoint of clinical remission was not statistically significant, indicating mixed results in the effectiveness of the treatment.
Background: Hepcidin plays a central role in iron homeostasis and erythropoiesis. Neutralizing hepcidin with a monoclonal antibody (mAb) may prevent ferroportin internalization, restore iron efflux from cells, and allow transferrin-mediated iron transport to the bone marrow. This multicenter, phase 1 study evaluated the safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of a fully humanized mAb (LY2787106) with high affinity for hepcidin in cancer patients with anemia.
View Article and Find Full Text PDFObjective: To determine whether collateral artery development is impaired in spontaneously hypertensive (SHR) relative to normotensive (WKY) rats.
Methods: Sequential mesenteric arteries were ligated to create a collateral pathway responsible for the perfusion of approximately 50 first-order arterioles. Collateral development was assessed by measurement of in vivo arterial diameter before and 1 week after ligation.
The effect of maturation on collateral development of resistance arteries was investigated. Three to four sequential mesenteric arteries were ligated to create collateral pathways in anesthetized young (approximately 200 g) and mature (approximately 600 g) rats. Blood flow was similarly elevated in collaterals of young and mature animals.
View Article and Find Full Text PDF